Nifed

Quick links to important sections

Nifed

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nifed

Property Description
Active ingredient Nifedipine
Form Tablets and Capsules (Oral Administration)
Pharmacological class Calcium Channel Blocker (Dihydropyridine)
Common use Management of high blood pressure and chest pain
Origin Synthetic Compound

Nifed is a trademarked prescription medicine with the active ingredient Nifedipine, formulated as a synthetic compound for systemic use. It is fundamentally classified as a Calcium Channel Blocker (CCB) and is clinically recognized for its efficacy in managing conditions affecting the cardiovascular system. Nifedipine is included on the List of Essential Medicines, reflecting its importance in basic healthcare systems.


What Type of Medicine is Nifedipine?

Nifedipine is a single-ingredient product belonging to the Dihydropyridine subgroup of Calcium Channel Blockers, a class of medicines that modulate the flow of calcium ions into specific muscle cells. This classification is based on the drug's core mechanism: the selective inhibition of calcium entry into the vascular smooth muscle cells. The primary function of this drug type is to act as a potent vasodilator, causing the widening and relaxation of arteries. Research consistently supports Nifedipine's role in this class of cardiovascular agents.


Composition and General Therapeutic Purpose

The fundamental purpose of Nifedipine is to improve circulation by relieving strain on the heart and regulating blood flow. By achieving vascular smooth muscle relaxation, the drug reduces overall systemic vascular resistance, which translates into a lower systemic blood pressure (antihypertensive effect). Furthermore, this dilation can include the coronary arteries, thereby improving oxygen supply to the heart muscle and providing a necessary antianginal effect, a typical scenario for its use.


Available Forms and Release Types

Nifedipine is prepared for oral administration and is supplied in solid oral forms, including capsules and various types of tablets. The distinction between immediate-release and the controlled extended-release tablets is crucial. The extended-release form uses a specialized matrix to steadily release the active ingredient over many hours. These extended-release formulations provide a sustained and predictable systemic effect, which is critical for consistent long-term management.

Regulatory References

  1. World Health Organization

What side effects are possible with Nifed?

Possible Side Effects and Safety Information

Adverse Reactions

Adverse reactions associated with Nifedipine (Nifed) are primarily related to its vasodilatory effect. Common reactions often include headache, flushing, and peripheral edema (swelling of the ankles or feet). Other common effects may involve the gastrointestinal system, such as nausea or constipation.

Less frequent (Uncommon or Rare) effects can include more serious events. Serious adverse reactions documented in regulatory sources include myocardial infarction (heart attack), severe hypotension (excessively low blood pressure), and the worsening or increase in frequency of existing angina pectoris (chest pain).

Safety Considerations and Restrictions

Nifed is generally contraindicated in patients with conditions such as cardiogenic shock, unstable angina pectoris, or during or within one month of a myocardial infarction. The immediate-release formulation, in particular, carries an increased risk of precipitating myocardial ischemia and is generally not recommended for use in the elderly.

Use is cautioned or restricted in patients with severe aortic stenosis, congestive heart failure, or moderate to severe hepatic (liver) impairment as this can alter the drug's metabolism and effects. Patients with rare hereditary conditions like galactose intolerance should not take lactose-containing extended-release formulations.

Drug and Food Interactions: Co-administration with potent CYP3A4 inducers, such as rifampin or St. John's Wort, should be avoided as they can significantly reduce Nifedipine concentration and efficacy. In addition, consuming grapefruit or grapefruit juice should be avoided as it can significantly increase the drug's systemic exposure, leading to an increased risk of adverse effects.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Nifedipine is officially documented in regulatory information as potentially leading to severe hemodynamic instability. The clinical manifestations primarily involve the cardiovascular system, resulting in severe hypotension and serious changes in heart rhythm, such as profound bradycardia or reflex tachycardia. Documented presentations also include effects on the Central Nervous System, such as dizziness, impaired consciousness, and somnolence. Life-threatening outcomes documented in regulatory sources include cardiogenic shock, asystole, and progression to deep coma.

Immediate medical attention is mandated by official regulatory guidance for any suspected overdose, due to the significant and potentially life-threatening risks. Emergency services must be contacted immediately.

The management strategy described in regulatory documents is strictly symptomatic and supportive, as no specific antidote is known for Nifedipine overdose. Management procedures often include initial gastrointestinal decontamination, such as gastric lavage, and the administration of agents like Intravenous Calcium Salts to manage symptomatic effects. Hospitalization is explicitly required, with continuous cardiac monitoring and Intensive Care Unit (ICU) admission specified for severe cases. Prolonged observation is necessary, particularly with extended-release formulations, due to the potential for delayed onset of toxicity. Special consideration is also noted for elderly patients and those with hepatic impairment due to increased potential for severe effects.

Therapeutic Uses of Nifed

What Nifed treats: main uses and benefits

Nifedipine is used to address conditions presenting with symptoms related to systemic imbalance arising from vascular issues. The therapeutic goal is to support the management of symptoms linked to high systemic pressure and symptoms that create noticeable physiological strain. It is generally applied in clinical settings for conditions such as chronic systemic hypertension, chronic stable angina, and vasospastic angina that occurs at rest.

Managing Symptomatic Domains

Nifed is relevant for conditions characterized by chronic systemic hypertension and is also applied in clinical settings for certain severe, acute elevations of arterial pressure. It helps address symptom clusters related to heightened physiological activity, providing supportive relief that assists in managing the symptoms related to elevated vascular pressure, which helps ease the overall symptom burden. The medicine is commonly used across conditions presenting with angina pectoris, where the key benefit is supporting symptomatic relief, which may assist with managing the frequency of distressing manifestations. It is relevant in contexts involving specialized uses, such as supporting patients with episodic peripheral circulatory distress like Raynaud’s phenomenon, where it is used when symptoms cluster into painful, acute spasms in the extremities.

“The primary goal is supporting symptomatic relief and contributes to improved comfort during periods of heightened symptoms.”

Quick Fact: Symptomatic Support Nifed is commonly used to help with symptoms related to both generalized high blood pressure and specific discomfort associated with symptoms linked to organ-specific functional stress. This provides supportive relief when symptoms interfere with routine activities.

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Nifedipine

The eligibility for Nifedipine is strictly defined by regulatory documents based on patient population, pre-existing conditions, and physiological status. The medicine is primarily approved for use in adults (18 years and over) for the chronic management of high blood pressure and certain types of chest pain (angina).

Use is prohibited (contraindicated) for several populations due to severe risk, as stated in official labeling:

  • Patients with a known hypersensitivity to nifedipine or other dihydropyridine medicines.
  • Individuals experiencing Cardiogenic Shock.
  • Patients who have Unstable Angina Pectoris or are within four weeks of an Acute Myocardial Infarction.
  • Patients taking the antituberculosis medicine Rifampicin.

Furthermore, Nifedipine is generally not recommended or contraindicated during pregnancy and lactation by many authorities. Regulatory documents state that safety and efficacy have not been established for the pediatric population (children and adolescents under 18 years).

Restricted Use and Caution: Use requires careful monitoring in adults with Impaired Liver Function and in those with Poor Cardiac Reserve or Severe Hypotension.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Nifedipine's official interaction profile is defined by its metabolic pathway and pharmacodynamic action, as documented in regulatory information. Combinations with certain substances are explicitly restricted to manage the risk of altered drug exposure or enhanced effects.


Official Interaction Statements

  • Contraindicated Combinations: Strong CYP3A4 inducers, such as Rifampicin and the herbal product St. John's Wort, are formally classified as contraindicated or must be avoided. Co-administration significantly reduces Nifedipine's systemic exposure (AUC/Cmax), leading to a loss of therapeutic effect.
  • Increased Exposure Risk: Co-administration with CYP3A4 inhibitors (e.g., Azole Antimycotics, HIV Protease Inhibitors) formally increases Nifedipine plasma concentrations. The food product Grapefruit/Grapefruit Juice must also be avoided for the same reason—it is documented to significantly increase exposure by inhibiting intestinal CYP3A4.
  • Additive Effects: Concomitant use with other antihypertensives or alcohol (Ethanol) is documented to result in an additive hypotensive effect, which may increase the risk of excessively low blood pressure.
  • Effect on Other Medicines: Nifedipine officially reduces the clearance of Digoxin, a P-glycoprotein substrate, leading to increased plasma Digoxin levels.
  • Population Notes: Clearance is documented to be decreased in elderly patients and those with hepatic impairment, resulting in higher systemic exposure for these populations.

This structure reflects the regulatory requirement to strictly define combinations that modify Nifedipine levels or potentiate its blood pressure-lowering effect, ensuring constraints are clearly communicated.

Mechanism of Action

How Nifed Works: Mechanism of Action

Nifed's mechanism involves antagonism of ion channels that regulate blood vessel tone.

Targeting Calcium Channels in Vascular Muscle

Nifed acts as an antagonist (blocker) that engages specific voltage-dependent L-type calcium channels on the surface of vascular smooth muscle cells. By binding to these channels, the drug inhibits the movement of calcium ions ( Ca^2+) from the outside into the muscle cell's interior. This intervention at the molecular level modifies the early steps of the excitation-contraction coupling pathway, a process required for muscle cell shortening.

Modulating Peripheral Vascular Resistance

The reduced calcium entry prevents the smooth muscle lining the arterioles (small arteries) from contracting, leading to their relaxation and widening (vasodilation). This mechanistic cascade primarily modulates peripheral vascular tone. The resulting physiological effect is a decrease in the resistance the blood encounters as it flows through the body, contributing to a reduction in systemic vascular load (afterload) and an increase in coronary blood flow.

Dosage and Administration Information

How to Use Nifed

The administration of Nifedipine is characterized by specific protocols, differentiating between its immediate-release (IR) and extended/modified-release (ER/MR) forms. The oral route is the standard method of administration for all major formulations.

Dosing and Frequency

Standard dosing schedules vary significantly by formulation:

  • Immediate-Release (IR) Capsules: Used in regimens requiring administration three to four times daily (t.i.d. to q.i.d.). The initial dose for angina is typically 10 mg three times daily, with a maximum dose of 180 mg per day.
  • Extended-Release (ER/MR) Tablets: These specialized formulations are administered once daily (q.d.) for sustained effect. Starting doses are commonly 30 mg to 60 mg once daily, and the maximum recommended dose ranges from 90 mg to 120 mg daily, depending on the specific product formulation.

Dosage adjustments are typically implemented gradually, often requiring an interval of 7 to 14 days between changes to assess effect.

Procedural and Administration Rules

Extended-Release tablets must be swallowed whole and must not be crushed, chewed, or divided to preserve the drug's intended release mechanism. While IR capsules may be taken with or without food, some ER formulations are specifically instructed to be taken on an empty stomach.

A critical dietary constraint is the absolute avoidance of grapefruit and grapefruit juice, as its consumption can alter the systemic exposure of Nifedipine.

Population-Specific Use

  • Older Adults (over 65 years): Caution is advised, and the use of the Immediate-Release form is generally avoided.
  • Hepatic Impairment: Patients with liver dysfunction require careful monitoring, and a dose reduction may be necessary, often involving starting at the lowest available dose.
  • Discontinuation: Therapy should be stopped by gradually decreasing the dosage, not by abrupt withdrawal.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nifedipine


Research Evidence for Managing Chronic High Blood Pressure

The evidence base used to evaluate Nifedipine in the context of chronic high blood pressure (hypertension) includes large Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. These research efforts primarily focused on the extended-release formulations of Nifedipine. Research examined outcomes related to physiological strain and systemic or functional imbalance, monitoring changes in Systolic and Diastolic Blood Pressure (BP) measurements over time.

Long-term studies monitored rates of major cardiovascular outcomes, such as nonfatal stroke and nonfatal myocardial infarction, across the observed populations. Trial reports documented shifts in blood pressure metrics measured during the study period and described patterns related to the long-term incidence of specific cardiovascular events.


Research Evidence for Managing Chronic Chest Pain (Angina)

Research exploring chronic chest pain (angina) includes studies for Chronic Stable Angina and for Vasospastic Angina. For Chronic Stable Angina, large, placebo-controlled trials have been conducted. These studies often evaluated the extended-release formulation in populations where other anti-anginal medicines were also in use. The studies monitored outcomes related to physical discomfort and daily functioning or activity level.

Studies reported how symptoms evolved in the observed populations, and findings documented patterns related to the need for certain coronary procedures. For Vasospastic Angina, research is often based on smaller, controlled trials. Evidence contributes to understanding symptom patterns by exploring outcomes linked to changes in angina recurrence. However, the sample sizes were modest, meaning the evidence quality varies across studies compared to the large-scale trials for chronic stable angina.


Evidence in Specific Patient Populations

Clinical research has also been applied in studies examining specific populations. Nifedipine was evaluated in studies involving older adults across the hypertension and stable angina trials; these individuals often formed a significant portion of the larger study populations.

Studies also examined Nifedipine in the context of severe hypertensive disorders of pregnancy, including preeclampsia. These studies monitored outcomes related to physiological strain or stress, such as the time required for blood pressure metrics to reach defined target levels and various maternal/fetal outcomes. Research is often focused on the acute, severe setting, and comparative evidence is lacking for all possible long-term scenarios.

Key Studies & References

  1. Hypertension in pregnancy: diagnosis and management (NICE Guideline NG133)
  2. Efficacy of nifedipine therapy in patients with refractory angina pectoris: Significance of the presence of coronary vasospasm
  3. Nifedipine Therapy for Coronary-Artery Spasm: Experience in 127 Patients

Frequently Asked Questions (FAQ)

Common questions about Nifed (FAQ)

Q: How quickly should I feel the effects of Nifed?

The time it takes for the medicine to begin its effect (onset of action) differs depending on the type of formulation. Immediate-release forms are described in official documents as potentially starting to act within 20 minutes. Extended-release tablets release the ingredient more slowly and gradually increase in concentration, reaching a plateau at approximately six hours.

Q: What happens if I miss several doses of Nifed?

Official guidance for a single forgotten dose indicates taking it as soon as it is remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped. Regulatory documents state that two doses should not be taken at once.

Q: How long can I continue using Nifed?

Official product information notes that treatment, when medically appropriate for chronic conditions, may be continued indefinitely.

Q: What is the risk of stopping Nifed suddenly?

Regulatory documentation indicates that discontinuance of therapy should be done by gradually decreasing the dosage. Abrupt cessation of the medicine after prolonged use is associated with the potential for a rebound increase in blood pressure or chest pain.

Q: Does Nifed cause sun sensitivity?

Official adverse reaction information lists skin sensitivity to the sun (photosensitivity) as a possible effect. As this is a documented possible effect, using appropriate protective measures when exposed to the sun may be considered.

Q: Is there a best time of day to use Nifed?

Official administration guidelines emphasize the need for consistent use, particularly for the once-daily extended-release forms. They also note the relationship to food, as some extended-release forms are advised to be taken on an empty stomach. Therefore, maintaining consistency with administration is emphasized in official guidance.

Q: Can Nifed cause weight changes?

While not generally listed as a common side effect, official patient information sometimes advises that a healthcare professional be informed to report unusual weight gain or loss while using the medicine.

Q: Is it normal to feel dizzy when starting Nifed?

Official product information documents that dizziness or lightheadedness are potential effects. These symptoms are more likely to occur when treatment is first initiated or when the dose is adjusted, due to the medicine's effect on blood pressure.

Q: Does Nifed affect sleep?

Adverse event reports have infrequently included documentation of sleep disturbances (such as insomnia) or unusual dreams (paroniria). These effects are typically classified as uncommon or rare.

Q: Can Nifed be used by older adults?

Regulatory documentation states that the immediate-release formulation should generally be avoided in older adults. Pharmacokinetic data indicates that the processing of the medicine is altered in this population, which may necessitate careful monitoring.

Q: Can Nifed cause mood swings or anxiety?

Official adverse reaction reports have included documentation of effects such as mood changes and nervousness. Rarely reported effects include anxiety or depression.

Q: Does Nifed require routine monitoring or blood tests?

Regulatory information suggests that careful monitoring of blood pressure is appropriate. This is particularly relevant during the beginning of treatment and when adjusting the dose.

Q: Why does Nifed have different strengths available?

The various strengths are documented as being available to accommodate the process of gradually adjusting the dosage (titration). This process is undertaken to meet a patient’s individual needs and response to treatment over time.

Q: Can Nifed affect fertility?

Regulatory and authoritative sources indicate that there is no clear evidence to suggest that taking this medicine reduces fertility in either men or women.

Q: Do people who take Nifed often experience headaches?

Headache is documented in official labeling as a common adverse reaction associated with the use of the medicine, likely due to its vascular effects.

Q: How long does Nifed stay in your system?

The medicine's elimination from the body is measured by its half-life. Official pharmacokinetic documentation states that the medicine's elimination half-life is approximately two hours, meaning half of the drug is eliminated from the body in that time.

Q: Is Nifed a type of preventative medicine?

The medicine is primarily used for the management of certain conditions, such as high blood pressure and chronic stable angina. In the context of angina, its action to reduce coronary artery spasm functions to prevent symptoms from recurring.

Q: Does using Nifed affect driving ability?

Official documentation states that because the medicine may cause effects such as dizziness or drowsiness, a patient should not attempt to drive or operate machinery if they are affected by these symptoms.

Q: Can Nifed cause problems with kidney function?

While the medicine's metabolism is primarily hepatic (in the liver), official documentation advises that caution should be exercised in treating patients with existing renal (kidney) disease because the absorption of the medicine could be modified in this population.

Q: Is Nifed a new or older medication?

The active ingredient has been documented in use for a long time. The initial formulation was an immediate-release type that required multiple daily doses, which has since been supplemented by modern extended-release versions.

Q: What if I experience side effects that aren't listed?

Official guidance indicates that a healthcare professional should be informed if any side effects are experienced. This includes effects that are severe, bothersome, or unlisted in the patient information provided with the medicine.

Q: Is it common to need to adjust the dose of Nifed?

Regulatory documentation describes the process of dosage adjustment (titration) as a routine and gradual practice. This process is undertaken as a means of managing individual needs and ensuring appropriate medication levels.

How should Nifed be stored and disposed of?

How to Store and Dispose of Nifedipine

The storage and disposal of Nifedipine must follow specific requirements defined in official labeling to maintain product stability and safety.

Storage Conditions

Nifedipine requires storage at controlled room temperature, typically between 20°C and 25°C (68°F and 77°F). The medicine must be protected from light and excessive moisture, and storage instructions explicitly state to avoid freezing. To maintain protection, the product must be kept in its original, tightly closed container.

Child Safety and Disposal

It is mandatory to keep Nifedipine out of the sight and reach of children.

Disposal of unused or expired medicine should be handled via a drug take-back program. Regulatory guidelines prohibit disposal by flushing the product down a sink or toilet. If a take-back program is unavailable, the medicine should be mixed with an unappealing substance, placed in a sealed bag, and discarded with household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Nifed found in:

A-Z Index: